The J.P. Morgan Healthcare Conference is a time for industry to reflect, assess, and forecast, and this year’s 37th annual conference was no exception.
Below is a summary of the most important news from JPM 2019, as selected by BulletinHealthcare’s expert analysts.
M&A Activity
Eli Lilly Rushed Loxo Acquisition Through To Make Big Splash At JPM19: BioPharma Dive, Axios, Endpoints News, STAT, Business Insider
Analysts: Mega-Deals At Bristol-Myers, Lilly Could Bode For Big Year In Pharma M&A: Business Insider, FirstWordPharma, Fierce Biotech
Analysts Offer Thoughts On BMS-Celgene Merger: MedCity News
Partnerships
Pfizer Staying In Neuroscience By Funding Startups: Business Insider
GlaxoSmithKline Looking For Early-Development Treatments And New Partnerships: Reuters, FirstWordPharma
Drug Developments
Sandoz, Pear Therapeutics Unveil Commercial Launch Of Digital Therapy For Opioid Use Disorder: Drug Delivery Business News, Monthly Prescribing Reference, BioSpectrum
J&J Expecting Big Things In Immunology From Tremfya: Fierce Pharma Marketing
Sage Preparing To Launch Two Postpartum Depression Drugs: Boston Business Journal
Other News of Note
Novartis CEO Vas Narasimhan’s Presentation At JPM19, CNBC Interview: BioSpace, FirstWordPharma, The Street
CVS Commits $100M For Community Health Programs: U.S. News & World Report, CNBC
Forecasting
Analysis: Executives Come Away From JPM19 With “Cautious Optimism:” Fierce Pharma
Biotech A Safe Bet, More Deals On the Horizon: Financial Times
Analysis Examines NASH Insights From JPM19: BioPharma Dive
For more insights like these, follow us on LinkedIn and watch this space!
